

## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001  
Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: <https://www.ebnl.org>  
Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

---

EBN/2020/S-LDF14

June 30, 2020

DCS - CRD  
The BSE Ltd  
25<sup>th</sup> floor, Phiroze Jeejebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001,

Sub: Outcome Of Board Meeting.

Ref: Scrip Code No. 524768

Dear Sir,

Pursuant to Regulation 33 of SEBI [LODR] Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today, have inter alia approved the Audited Financial Results of the Company for the quarter / year ended March 31, 2020.

We are attaching herewith the following for your record.

1. Audited Financial Results along with the Segment Wise & Revenue Results, Statement of Assets & Liabilities and Cash Flow Statement
2. Auditor's Report with year to date Result
3. Declaration in respect of Auditor's Report with Un-Modified Opinion.

This is for your information and record.

Thanking you,

Yours faithfully,  
For Emmessar Biotech & Nutrition Ltd



Compliance Officer  
Encl: As above.


EMMESSAR BIOTECH & NUTRITION LTD						
Regd Office: Plot No. T-3/2, MIDC, Taloja, Raigard District, Maharashtra - 410 208						
CIN: L24110MH1992PLC06594229						
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2020					Rs. In lacs	
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Audited	Audited	Audited	Audited
<b>PART A</b>						
1	Revenue from Operations	86.04	59.28	15.27	339.59	62.95
2	Other Income	37.10	38.06	35.86	146.51	129.99
	<b>Total Income (1 + 2) A</b>	<b>123.14</b>	<b>97.34</b>	<b>51.13</b>	<b>486.10</b>	<b>192.94</b>
<b>PART B</b>						
3	Expenses					
	(a) Cost of material consumed	87.82	58.07	39.55	209.76	36.60
	(b) Purchase of Stock-trade	0.80	0.81	0.45	14.22	17.95
	(c) Change in inventories of Finished goods	(65.39)	(40.84)	(46.05)	(69.90)	(42.14)
	(d) Employee Benefit Expenses	12.86	17.61	10.56	57.54	57.55
	(e) Depreciation & amortisation of Assets	1.43	1.45	1.40	5.78	7.86
	(f) Other Expenditure	66.50	36.39	26.76	168.55	57.07
	<b>Total Expenses (a to f)</b>	<b>104.02</b>	<b>73.49</b>	<b>32.67</b>	<b>385.94</b>	<b>134.89</b>
4	Profit from operations from exceptional items and taxes (A - B)	19.12	23.85	18.46	100.16	58.05
5	Exceptional Items	26.40	0.00	28.67	26.40	28.67
6	Profit / loss before tax (4 - 5)	(7.28)	23.85	(10.21)	73.76	29.38
7	Tax Expense					
	1. Current tax (MAT)	(16.00)	0.00	(6.00)	(16.00)	(6.00)
	2. Deferred tax (asset)	2.05	0.00	1.91	2.05	1.91
	3. Excess / (Short) provision of earlier years	0.00	0.00	0.00	(0.10)	0.00
	4. MAT Credit available	15.66	0.00	28.00	15.66	28.00
8	Net Profit / (loss) after tax (6 - 7)	(5.57)	23.85	13.70	75.37	53.29
9	Other comprehensive income	(0.05)	0.00	0.96	(0.05)	0.96
10	Total comprehensive income for the period and other comprehensive income	(5.52)	23.85	12.74	75.42	52.33
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61
	Face Value of the share	10.00	10.00	10.00	10.00	10.00
12	Earnings per Equity Share					
	a) Basic	(0.11)	0.48	0.25	1.51	1.05
	b) Diluted	(0.11)	0.48	0.25	1.51	1.05

#### NOTES

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 30th June 2020 through Zoom conference.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS-34) as prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rule 2015 and the Companies (Indian Accounting Standards) Amendments Rule 2016 as amended thereafter.
- During the year the company operated in three segments ie. Healthcare, Fine Chemicals and Rent on leasehold land.
- The audit as required under Regulation 33 of the SEBI (Listing obligation and disclosure agreements) regulations, 2015 has been completed by the Auditors of the company.
- No Investors complaints were received as of Quarter ended 31st March 2020
- The company had a fire accident at the vendors place on 11.02.2020. Documents submitted with Insurance company and the claim under process.
- Previous years' figures have been regrouped wherever considered necessary.

Place: Mumbai  
Date : 30-06-2020

for Emmessar Biotech & Nutrition Ltd

  
MSR Ayyangar  
Managing Director.





**EMMESSAR BIOTECH & NUTRITION LTD**


Quarter and Year ended Segment wise Revenue Results and  
Capital Employed under Clause 41 of the Listing Agreement.

[Rs. In Lakhs]

	Quarter ended			Year Ended	
	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
	Audited	Audited	Audited	Audited	Audited
<b>1. Segment Revenue</b> (Net Sales / Income)					
a. Healthcare	2.49	5.43	3.72	53.48	51.40
b. Fine Chemicals	83.55	53.85	11.55	286.11	11.55
c. Rent on Leasehold land	33.78	33.78	33.78	135.13	125.92
d. Others	3.32	4.28	2.08	11.38	4.08
Total:	123.14	97.34	51.13	486.10	192.95
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
Net Sales / Income from Operations	123.14	97.34	51.13	486.10	192.95
<b>2. Segment Results (Profit / Loss)</b> before Tax and Interest					
a. Healthcare	1.82	3.10	1.14	34.94	29.21
b. Fine Chemicals	0.69	8.44	0.32	(11.16)	0.32
c. Rent on Leasehold land	33.78	33.36	33.78	135.13	125.92
d. Others	3.32	4.28	2.08	11.38	4.08
Total:	39.61	49.18	37.32	170.29	159.53
Less:					
Interest	0.00	0.00	0.00	0.00	0.00
Other Unallocable Expenditure net off Unallocable Income	20.49	25.33	18.86	70.13	101.48
Total Profit / (loss) before Tax	19.12	23.85	18.46	100.16	58.05
<b>3. Capital Employed</b> (Segment Assets - Segment Liabilities)					
a. Healthcare	8.23	6.42	7.97	8.23	7.97
b. Fine Chemicals	28.95	36.88	71.51	28.95	71.51
c. Rent on Leasehold land	2.08	2.59	3.01	2.08	3.01
d. Others	287.74	231.32	179.41	287.74	179.41
Total:	326.99	277.21	261.90	326.99	261.90

The above results were taken on record at a meeting of the Board of Directors held on June 30, 2020

Mumbai  
30th June 2020

  
 By order of the Board  
 MSR Ayyangar  
 Managing Director



<b>EMMESSAR BIOTECH &amp; NUTRITION LTD</b>			
<b>Statements of Assets &amp; Liabilities</b>			
<b>(Rs. In Lakhs)</b>			
	<b>Particulars</b>	<b>As at 31st Mar 2020</b>	<b>As at 31st Mar 2019</b>
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Property, Plant & Equipment	127.91	134.30
	(b) Investment Property	63.50	64.43
	(c) Other Financial Assets	1.28	1.50
	(d) Deferred Tax Assets (net)	93.79	76.03
	<b>Sub-total Non-current Assets</b>	<b>286.48</b>	<b>276.26</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	114.91	72.81
	(b) Investments	0.73	0.69
	(c) Trade Receivables	2.65	3.82
	(d) Cash & Cash equivalents	5.04	7.77
	(e) Bank balance other than cash & Cash Equi	183.08	63.67
	(f) Loans	0.19	0.51
	(g) Income tax assets (net)	5.47	12.89
	(h) Other Financial assets	5.46	1.56
	(e) Other current assets	9.15	76.47
	<b>Sub-total Current Assets</b>	<b>326.66</b>	<b>240.19</b>
	<b>TOTAL ASSETS</b>	<b>613.14</b>	<b>516.45</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>SHAREHOLDER'S FUNDS:</b>		
	(a) Equity Share Capital	499.61	499.61
	(b) Other Equity	(73.37)	(148.79)
	<b>Sub-total Shareholder's funds</b>	<b>426.24</b>	<b>350.82</b>
<b>2</b>	<b>Non-current Liabilities</b>		
	(a) Other Financial liabilities	61.42	61.42
	(b) Long Term Provisions	15.74	14.28
	<b>Sub-total Non-current liabilities</b>	<b>77.17</b>	<b>75.70</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Borrowings	-	7.17
	(b) Trade payables	80.38	57.52
	(c) Other financial Liabilities	20.16	17.18
	(d) Other current liabilities	1.64	1.24
	(c) Short-term provisions	7.56	6.82
	<b>Sub-total Current Liabilities</b>	<b>109.73</b>	<b>89.93</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>613.14</b>	<b>516.45</b>





CASH FLOW STATEMENT FOR THE YEAR ENDED 31.3.2020		2019-20	2018-19
		Rupees	Rupees
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net Profit before Tax and Extraordinary Items	10,015,911	5,805,105
	Add/(-)Less: Depreciation	577,750	786,369
	Interest / Dividend	-1,052,908	-355,105
	Other comprehensive income	7,602	-132,805
	Exceptional Items	-2,639,587	-975,020
	<b>Operating Profit / Loss before working Capital changes</b>	<b>6,908,768</b>	<b>5,128,544</b>
	<b>Adjustment for (Increase) / Decrease in operating Assets</b>		
	Inventories	-4,209,469	-6,411,809
	Trade Receivables	117,383	-48,203
	Non current loans and Income Tax Assets	-1,753,745	816,746
	Other Financial Assets	-389,653	-145,718
	Current Assets - Loans and other assets	7,505,930	-2,122,031
	<b>Adjustment for Increase / (Decrease) in operating Liabilities</b>		
	Non current provisions	145,704	-394,598
	Trade Payables	2,286,059	5,678,856
	Borrowings and Other Financial Liabilities	-419,212	1,209,383
	Other Current Liabilities	39,404	51,161
	Current Provisions	73,505	121,919
	<b>Cash generated before tax payments</b>	<b>10,304,674</b>	<b>3,884,250</b>
	Less: Income tax paid	0	0
	<b>Cash generated from operations</b>	<b>10,304,674</b>	<b>3,884,250</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Purchase of Fixed Assets	-5,200	-7,800
	Investments in Mutual Funds	-3,312	-3,627
	Interest / Dividend Received	1,370,795	355,105
	Investments in Fixed Deposits (maturing within 12 months)	-11,940,419	-4,087,517
	<b>Net Cash inflow/(out flow) in Investing activities</b>	<b>-10,578,136</b>	<b>-3,743,839</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Net Cash used in financing activities		
	<b>Net increase in cash and cash equivalents</b>	<b>-273,462</b>	<b>140,411</b>
	Cash and cash equivalents as at the beginning of the year	777,339	636,928
	Cash and cash equivalents as at the end of the year	503,877	777,339

As Per Our Report of Even Date attached

For V. Sankar Aiyar & Co  
Chartered Accountants  
Firm Regn No. 109208W

V. Mohan  
Partner  
M. No. 17748  
Place : Mumbai  
Date : 30th June 2020

For and on behalf of the Board

Ashok M. Kadakia  
Chairman  
DIN:00317237

Vijay K. Agrawal  
Director  
DIN: 01710632

MSR Ayyangar  
Managing Director  
DIN: 00090266





## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: <https://www.ebni.org>

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

EBN/2020/S-LDF14A

June 30, 2020

DCS - CRD  
The BSE Ltd  
25<sup>th</sup> floor, Phiroze Jeejebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001.

Sub: Declaration Pursuant to Regulation 33 (3) (d) of SEBI [LODR] Regulations, 2015.

Ref: Scrip Code No. 524768

Dear Sir,

In compliance with the provision of Regulation 33 (3) (d) of SEBI [LODR] Regulations, 2015, we hereby declare that, M/s. V. Sankar Aiyar & Co., Statutory Auditors of the company, have issued an Audit Report dated: June 30, 2020, with Unmodified Opinion of the Audited Financial Results of the Company (Standalone), for the quarter / year ended March 31, 2020.

This is for your information and record.

Thanking you,

Yours faithfully,  
For Emmessar Biotech & Nutrition Ltd



Compliance Officer  
Encl: As above.



Tel : 2200 4465, 2206 7440  
Fax : 91-22- 2200 0649  
E-mail : [Mumbai@vsa.co.in](mailto:Mumbai@vsa.co.in)  
Website : [www.vsa.co.in](http://www.vsa.co.in)

**V. Sankar Aiyar & Co.**  
CHARTERED ACCOUNTANTS  
2-C, Court Chambers  
35, New Marine Lines  
Mumbai – 400 020

## INDEPENDENT AUDITOR'S REPORT

To The Board of Directors of Emmessar Biotech & Nutrition Limited

### Opinion

We have audited the accompanying financial results of Emmessar Biotech & Nutrition limited ("the Company"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended 31 March, 2020

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements in India under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

### Board of Director's Responsibilities for the Financial Results

These Standalone financial results have been prepared on the basis of the standalone annual financial statements of the Company. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.



### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



**Other Matters**

The Financial Results include the results for the quarter ended 31<sup>st</sup> March, 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year.

For V. Sankar Aiyar & Co.,  
Chartered Accountants  
(FRN 109208W)



Place: Mumbai

Date: June 30, 2020

(V. Mohan)

(M.No.017748)  
UDIN: 20017748AAAAAV7638